Mauna Kea says study lifts Cellvizio pancreatic cyst diagnostic accuracy to 96%

PUBT · 1d ago
Mauna Kea says study lifts Cellvizio pancreatic cyst diagnostic accuracy to 96%
  • Mauna Kea Technologies highlighted two newly published, peer-reviewed clinical studies supporting its Cellvizio imaging platform for pancreatic cyst diagnosis.
  • An international reader-consistency study found Cellvizio improved physicians’ ability to classify cysts, with stronger agreement across clinicians.
  • A separate clinical study reported that combining Cellvizio with an AI algorithm improved identification of higher-risk lesions compared with conventional assessment.
  • Results were presented as published study findings, with no future conference presentation disclosed.
  • The publications add clinical validation that could support broader US adoption and advance the company’s AI-assisted decision-support roadmap.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mauna Kea Technologies SA published the original content used to generate this news brief via Business Wire (Ref. ID: 202607281145BIZWIRE_USPR_____20260728_BW514926) on July 28, 2026, and is solely responsible for the information contained therein.